Symbiotec Pharmalab Ltd.
NSE & BSE₹938–988
₹ 1,297 Cr
15 Shares
₹ 14,070
₹2
Financial Summary
| Particulars | FY 2025-26 | FY 2024-25 |
|---|---|---|
| 8,691.49 | 7,515.54 | |
| 31.09 | 44.25 | |
| 8,722.58 | 7,559.79 | |
| 6,304.79 | 5,488.36 | |
| 1,533.63 | 1,469.75 | |
| 1,099.03 | 967.85 |
Subscription Details
Subscription
IPO Timeline
IPO Offer Start
24 Aug 2026
IPO Offer Ends
27 Aug 2026
1 Sept 2026
Use of Proceeds
| # | Purpose | Amount (₹ Million) |
|---|---|---|
| 1 | Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding | 1,125 |
| 2 | General corporate purposes | 295.25 |
Promoters
Book Running Lead Managers
Promoter Shareholding
Pre-IPO
34.47%
Promoter stake
Post-IPO
33.28%
Promoter stake
Offered to Public
1,31,24,929
shares
Post Share Capital
2,13,83,823
shares
About the Company
We are a research and development-driven, science-based pharmaceutical and biotechnology company with capabilities across three platforms- organic chemistry, biotechnology and complex injectables. We have a global leadership position in corticosteroid and steroidal-hormone active pharmaceutical ingredients (“APIs”) in volume terms in Fiscal 2025, with a global volume market share of 36.2% in corticosteroid and 44.2% in steroidal-hormone APIs. (Source: F&S Report) We are the only Indian and global company to have a presence across the top 10 corticosteroid and steroidal-hormone APIs in Fiscal 2025, (Source: F&S Report) demonstrating the depth of our portfolio. We manufacture these products using fermentation and multi-step complex chemical reactions. With over 30 years of industry experience, we have evolved from a lab-scale steroidal-hormone API anufacturer in 1995 into an industrial-scale, backward-integrated platform with approvals from the United States Food and Drug Administration (“US FDA”), European Union Good Manufacturing Practices (“EU-GMP”), Ministry of Food and Drug Safety, Korea and other global organisations. We have leveraged our deep capabilities across organic chemistry,biotechnology, and complex injectables to operate as a contract development and manufacturing organisation (“CDMO”) variably for specialty pharmaceutical and nutraceutical companies globally, offering products and services across the three platforms in which we also manufacture our own products. As of June 30, 2025, we had two operational industrial-scale API manufacturing facilities with a maximum chemical synthesis capacity of 584.67 metric tonnes (“MT”) and fermentation capacity of 300 kilolitres (“KL”). Further, as of the date of this Draft Red Herring Prospectus, we have newly commissioned two additional manufacturing facilities, leading to an aggregate maximum chemical synthesis capacity of 584.67 MT, maximum fermentation capacity of 700 KL, and complex injectables capacity of 20 million vials per annum, enabling us to function as a vertically integrated ‘microbe-topharmacy’ and ‘farm-to-pharmacy’ platform with cost-efficient operations. Our biotechnology facilities are equipped with fermenters of 5 KL, 35 KL and 100 KL, providing us flexibility in the scale of our operations. Further, we are in the process of expanding our biologics capacity by adding a proposed dedicated 14 KL (comprising two reactors of 7 KL each) fermentation capacity for biologics manufacturing in Ujjain.
Use of Proceeds
1. Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by our Company; and2. General corporate purposes.
Symbiotec Pharmalab Ltd. Latest News
News
Symbiotec Pharmalab soars as its arm inks pact with leading global pharmaceutical company
The agreement marks a decisive step in the commercialization of Knovea’s DCV platform
Symbiotec Pharmalab’s arm inks pact with leading global pharmaceutical company
The agreement marks a decisive step in the commercialization of Knovea’s DCV platform
Symbiotec Pharmalab trades higher on the BSE
The company has received EIR from USFDA for Pithampur facility with VAI status
Symbiotec Pharmalab receives EIR from USFDA for Pithampur facility with VAI status
The inspection was conducted at the company’s manufacturing facility at Pithampur, from August 10, 2026 to August 14, 2026
Symbiotec Pharmalab make flat debut on the BSE
The scrip is currently trading at Rs. 982.05, down by 5.95 points or 0.60% from its issue price
Symbiotec Pharmalab coming with IPO to raise upto Rs 1,851 crore
The issue will open for subscription on August 24, 2026 and will close on August 27, 2026
IPO FAQs
The Symbiotec Pharmalab Ltd. IPO has a total of ₹1,297 crore, calculated at the upper end of the .
The Symbiotec Pharmalab Ltd. IPO is priced at ₹938–988 per share. bids must fall within this , against a of ₹2 per share.
The for the Symbiotec Pharmalab Ltd. IPO is 15 shares, which is also the minimum order quantity — you have to apply for at least 15 shares, and in multiples of 15 beyond that.
The minimum investment in the Symbiotec Pharmalab Ltd. IPO is about ₹14,070 — one lot of 15 shares, calculated at the lower end of the .
Bidding at the cut-off or upper price raises the amount blocked in your account.
The Symbiotec Pharmalab Ltd. opens on 24 Aug 2026 and closes on 27 Aug 2026.
Applications have to be in before 5:00 PM IST on the closing day, and your UPI mandate needs to be approved by then as well.
Symbiotec Pharmalab Ltd. shares were listed on 1 Sept 2026 on BSE and NSE.
MUFG Intime India Pvt Ltd. is the for the Symbiotec Pharmalab Ltd. IPO.
The registrar processes the , refunds and the credit of shares to your demat account, so allotment-status queries go to them — phone +91 810 811 8484 and email rnt.helpdesk@in.mpms.mufg.com.
Symbiotec Pharmalab Ltd. IPO shares are listed on BSE and NSE.
Each Symbiotec Pharmalab Ltd. share has a of ₹2.
Face value is the nominal value recorded in the company's books and is separate from the issue price you pay.
held 34.47% of Symbiotec Pharmalab Ltd. before the IPO, which falls to 33.28% after the issue.
1,31,24,929 shares of Symbiotec Pharmalab Ltd. are being offered to the public in this issue.
The Symbiotec Pharmalab Ltd. IPO has been subscribed 71.26x overall — 172.03x, 73.63x, 12.96x and employees 15.41x.
figures update through the issue period until it closes.
- 1.Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by our Company
- 2.General corporate purposes
JM Financial Ltd., Avendus Capital Pvt Ltd., Motilal Oswal Investment Advisors Pvt Ltd and Nomura Financial Advisory & Securities (India) Pvt Ltd. are the for the Symbiotec Pharmalab Ltd. IPO.
Pre-apply means placing your Symbiotec Pharmalab Ltd. application before the subscription window actually opens. The bid is held and forwarded to the exchange on the opening day, so you don't have to submit it in the rush of the first morning.
Applying early doesn't improve your chances — when an issue is oversubscribed, the for investors is decided by a lottery, not by who applied first. Your money is only blocked once the application reaches the exchange.
You can apply in the Symbiotec Pharmalab Ltd. IPO online using either UPI or ASBA as the payment method. ASBA applications are made through the net banking of a bank account that supports IPO applications — the bank blocks the amount in your account instead of debiting it. UPI applications are offered by brokers that don't provide banking services: you enter your UPI ID and then approve the mandate request in your UPI app.
Either route needs a demat account. You bid for at least one lot, at a price within the or at the cut-off price, and the money stays blocked in your bank account until the is finalised.
Your broker or bank confirms the bid once it has been submitted to the exchange, usually within a few minutes during the bidding window. A UPI application only goes live after you approve the mandate request — ignore it and the bid lapses, even though it looks placed.
You can check the Symbiotec Pharmalab Ltd. bid independently on the NSE or BSE IPO bid-verification page a day after applying. An ASBA application also shows up as a blocked amount in your bank statement.